'Microclots' in Long Covid: The Latest Research | With Prof Resia Pretorius & Prof Doug Kell

In this second film in the microclot series, Dr. Assad Khan and I speak with Professors Riccia Pretorius and Doug Kell about their

research

on abnormal tracing in

long

Covid, we talk about the discovery itself, how the results of the microscopic analysis and how

long

covered patients are compared. For those suffering from mecfs and those suffering from similar symptoms that have been covered for a long time after the vaccine, we also cover what the hopes are for greater acceptance of the science and what other laboratories are

research

ing this same topic in this moment, so let's dig in, teachers.

Thank you both very much for joining us. It is an absolute privilege to speak with you. I was wondering if each of you could tell us a brief story of what brought you to this point in terms of the jobs you've done. published, you know about the recent microwatch findings, how your career has progressed to get you to where you are now. The backstory is that around 2011, Rachel and I were working on iron metabolism and iron metal ions, and Risha published a paper. in which he inadvertently failed to cite a review of mine with twenty-five hundred references on the subject, so I sent him a note to the effect that he might find it of interest, and in short, it's kind of a long story, he took the base and we started working together in the area of ​​iron and blood coagulation initially, which then led to the discovery that the plots in a variety of chronic inflammatory diseases have an amyloid character and then, of course, when it was done obvious from the beginning.

Wow, acute and covered diseases for a long time were possible diseases, uh, we, from our research efforts, we took a look at them and we discovered, of course, especially in acute tones, the amyloid microcloths that we discovered bacterial LPS, uh, uh , off scale in the Imputation has been one of my areas of focus and when acute coverage came along it was just the natural progression and I worked with yakulopshire who is one of my clinical collaborators, he previously gave us samples from his diabetes clinic , so when, when he I started to see the acute happening with patients in the icus.

We had a chat and he said, "Well, I'm patient. Do you want to see the conspiracy? I'm fighting the conspiracy, that's right at the beginning of 2020 and that's how our journey with Acute Greed happened and then it was covered for a long time." , it actually happened by accident because your patients didn't transition to uncovered services, but you started to notice that the patients that I referred to you came to me and said we have these persistent symptoms, so that was just the clotting progression in other conditions, inflammatory conditions to acute code and the long cover just came through our door on the topic of prolonged greed, maybe for those who are not familiar with your work, could you describe what you saw when you looked at Into the Blood? of patients covered for a long time, I initially had the idea to compare the molecular blood pathology biomarker content of the blood of patients with covert and uncovered acute disease and the way to do it in a typical research study would be to look at proteomics, So what is proteomics?

It is a laboratory method that is not really available for general pathology testing, but it is a research method that can look at the protein content of the molecules of a specific protein mixture, which in our case is blood, one of the methods used by any protonomics laboratory. What you would use is to digest your sample first and one of the methods is trips and digestion so it's a pretty tough enzyme and it's supposedly used to digest any protein and to our surprise we found that the acute and covered population length of the sample. we didn't digest and then from there we developed another digestion step that we were able to digest and then we found all the molecules intact within the population covered for a long time and its population that we believe could be the causative reason for all the inflammatory reactions that we see within In this population before that, we just used our bog standard microscopy laboratory method where we looked under the microscope at the blood of acute covert patients and non-covert patients and we found these huge microscopic patches that were in the blood of these two populations when we compared them to diabetes samples that had fewer clots and controls even less and just saying that even healthy individuals have clotting not as severe as would be found in acute cases and the long code is not at all a high clot burden in these two populations so how do you draw a line between what is normal and what is not? types of microclot proliferation, I mean mecfs for example, I don't know what other conditions you've looked at this way to be able to say, oh, we've seen this before or is this something completely new with lancavid from a long time ago.

Over the years, we've seen a lot of inflammatory conditions, diabetes, rheumatoid arthritis, psoriasis, neuroinflammatory conditions like Parkinson's, Alzheimer's in all of these conditions, a new one of the hallmarks of an inflammatory condition like all the ones I mentioned. The wall mark is an abnormal or coagulation pathology. That tends to be the case in all of these conditions simply because of the inflammatory molecules associated with the disease, so there are several different scenarios, different types of inflammatory molecules in all the different conditions, diabetes, obviously, most people struggle with high levels of sugar, so for a specific time, you will have a specific configuration of inflammatory molecules in all of these conditions, there are higher levels of clotting and when you compare the higher levels to a control, the control is much less obvious, microscopy is a difficult quantitative, it is more qualitative, it is more difficult to quantify, but we have worked on a classification system and hopefully soon we will be able to have a quantifiable flow cytometry method for microplots in particular , the plots we see are not like normal plots, normally there are blood clots inside and outside all the time, so when you cut your finger, it starts clotting immediately and you don't have to wait, so when you're done, the clot is removed and when you look at those normal clots in an electron microscope, they look like a plate of spaghetti as you would see in color that's really simple, whereas when you look at the type of plots that you see in these different conditions, they have a completely different morphology than in the electron microscope, as if spaghetti was parboiled and everything stuck together in those days. call it dense matter deposits and now we know that it is a type of amyloid configuration of the protease and those configurations are sustainable thanks to a stable bioflavian tea that makes them look bright green and they are not there and B are well known to be highly resistant to proteolysis and we also showed that the spike protein induces them, so we know precisely and the exact conformation, if we don't know, is definitely different in these different diseases, but we absolutely know that in the case of

covid

, the protein peak is enough, you did a similar study on the blood of mecfs patients, how similar or different were those findings, so for microdrafts, mecfs patients definitely have less microdrafts than you would find in a long coat. or in a patient with acute coverage much less, but the clots and microclus formation are comparable to someone with rheumatoid arthritis, diabetes, the level, however, what was a quite interesting finding for us was that patients with mecfs and long-term coverage patients have significant platelet hyperactivation. much more than what is known in a control and levels similar to those we have found in patients with acute coverage and with prolonged coverage, so the similarities are on the platelet side and the microclusions are less than those we would find in patients with prolonged coverage, which could be related to the spike protein, however, the area occupied by the microplots in the mecfs was 10 times after controls, which was not a small effect, yes, very interesting, for which there is also another group of patients who have not had much press and these are the people who have developed symptoms similar to those covered for a long time, apparently only from a vaccine and not from a covered infection.

I'm not sure if you've had a chance to look at any of your blood samples to see what's going on there. We haven't looked at those patients in large numbers, we've looked at some of them, so the good news is that we have received a grant from a South African Medical Research Council to compare groups of the long-covered population with a group of patients. who had the vax vaccine and now suffered damage from the vaccine and we're going to compare that to the controls so hopefully we'll have that data soon. I know people like to say it's long, they call it long coverage, but I think there has long been a clear distinction between actual acute infection and vaccine harm after vaccination and I think we need to unravel the exact differences and similarities between these two groups.

I think it will mean a lot to the vaccine insured. Pathology can be determined because that particular group faces a lot of disbelief and deception, even above the usual level experienced by long-covered patients. Now I ask you two on behalf of the audience where can people get tested for microclusions, it's probably not an easy question, well the easy answer almost doesn't exist at the moment, but we hope to fix that, so I just traveled to the US. I was just there on a two week visit. I went to the Petrino laboratory on Mount Sinai. I went to Professor Akiko at the Southeastern Laboratory at Yale and I went to the Harvard laboratory, which is a laboratory of Dr.

Jonker, who is a pulmonologist in a pediatric pulmonologist and I am also working with Dr. Mark Van elsucker and the Foundation of Polybio Research Amy Prowell. So, in all those laboratories the methodology has been implemented, the microscopes are working. Fortunately, there are research laboratories in the United Kingdom that are already set up. Caroline Dalton is one of the researchers who has already done fabulous work in Sheffield. Hallam has looked at blood samples from a patient and controls and has also compared disease capacity, obviously self-reported by patients with micrograph burden, but the wonderful thing about his setup is that he actually has an automated system, you know if your data will Soon there will also be a group from Manchester working with many clinicians, as well as in the team clot settings, who have developed a plate reader system and, hopefully, that data will surely be published by students, so that there are groups of laboratories that have repeated and are working on The next step is obviously that they must publish their research and, hopefully, the next step is that more research institutions and pathology laboratories will be interested.

The next step for us in South Africa was, with our help and the wonderful work covered for a long time. Community Polybar Research Foundation, as well as Balvian Kernels, we crowdfunded for a flow cytometer, it is in the lab, it is already installed, we will receive training in early January and hopefully we will be able to develop an automated system on flow cytometry that does not based on the microscopy method is difficult and may not be easily accessible. Hopefully we will have a method that people can use for microparticle analysis and platelet analysis and we hope to have that method widely available very soon.

Great news, yes, it is incredibly. It's encouraging, I guess what's so connected to that issue is the fact that it feels especially in the UK, when patients go and talk to doctors, they're met with some degree of eye rolling, maybe or raising their hands. eyebrows when the topic of microcloths comes up. What is it? we're going to take to get the medical establishments The medical establishment in general to take this more seriously and why do you think maybe they haven't done well so far? The short answer is that we don't know, but I think the longer answer is that we need to.

Research labs like the Dalton lab, like the adrenal lab like akikuslan, to do it and publish it because I think the only thing that worries a lot of people is just a small research lab with a few collaborators here and there in the UK. find this information and why pay attention to it, but I hope that our research published now has some hope that many people have realized that it is not just a small finding that uncovered patients really suffer fromcoagulation pathology and it is well known that we have a higher chance of suffering from strokes and other types of pathologies related to coagulation and I think people just need to do the research, maybe then and we need clinical trials, that's what will eventually make them turn towards use.

The methods, certainly, the clinical trials, but in the short term, the point-of-care doctors, the GPS, are ridiculously stretched. Due to the kleptocracy currently posing as a government, they know nothing about these new methods, which would force them not to use the label. which they are not willing to do and they do not have the techniques available to even send their people and have the measures to do it, so in a sense they are between a rock and a hard place right now in the next. Film from the series that we resume with Greasier and Doug to talk about a convincing hypothesis about the mechanism behind the exacerbation of post-exertional symptoms, where they see the existence of microclasses within the enormous puzzle that is the causality of long

covid

and what they are the dream drugs.

They'd like you to try it for a final word, if you don't mind, because I'm very bad at this side of self-promotion if you didn't know I had written a book with Professor Danny Altman. so please google the long covered manual and take a look, it's everything you wanted to know about long covid in one place. There are also some Amazon links in the description that will take you to being able to purchase print copies of audiobooks and e-books, stay safe until next time.